Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Feb;9(2):102195.
doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11.

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

J Herrstedt  1 , R Clark-Snow  2 , C H Ruhlmann  3 , A Molassiotis  4 , I Olver  5 , B L Rapoport  6 , M Aapro  7 , K Dennis  8 , P J Hesketh  9 , R M Navari  10 , L Schwartzberg  11 , M L Affronti  12 , M A Garcia-Del-Barrio  13 , A Chan  14 , L Celio  15 , R Chow  16 , M Fleury  17 , R J Gralla  18 , R Giusti  19 , F Jahn  20 , H Iihara  21 , E Maranzano  22 , V Radhakrishnan  23 , M Saito  24 , P Sayegh  25 , S Bosnjak  26 , L Zhang  27 , J Lee  28 , V Ostwal  29 , T Smit  30 , A Zilic  26 , K Jordan  31 , F Scotté  32 ; participants of the MASCC/ESMO Consensus Conference 2022. Electronic address: clinicalguidelines@esmo.org
Affiliations
Practice Guideline

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

J Herrstedt et al. ESMO Open. 2024 Feb.

Abstract

  1. •

    Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.

  2. •

    The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting.

  3. •

    The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates.

  4. •

    Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade).

  5. •

    All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.

Keywords: MASCC–ESMO Clinical Practice Guideline; chemotherapy; nausea and vomiting; prevention; radiotherapy.

PubMed Disclaimer

References

    1. Roila F., Molassiotis A., Herrstedt J., et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–v133. - PubMed
    1. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–v243. - PubMed
    1. Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71. - PMC - PubMed
    1. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–144. (adapted from: Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis.1994;1918:1421) - PubMed
    1. Hesketh P.J., Kris M.G., Basch E., et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797. - PubMed

Publication types